By Ludwig Burger FRANKFURT, Jan 29 (Reuters) - Roche's adjusted operating income rose by a lower-than-expected 5% in 2025 as ...

BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...

The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth ...

A late-stage trial of CT-388 is expected to start this quarter.

The Swiss drugmaker expects sales and core earnings per share to grow at constant currencies this year, partly due to the strength of its drug pipeline.

Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of ...

Roche reported 2025 sales of CHF 61.5 billion, driven by strong drug demand, rising profits, higher EPS, and a proposed ...

A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...

Roche aims to become a “top three player” in obesity, Teresa Graham, CEO of the group’s Pharma unit, said Thursday during a ...

Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after reporting Tuesday that the drug led ...

Roche’s Genentech plans to start its Phase 3 this quarter, but primary completion will happen by 2028. Click here to find out ...

Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as ...